Printer Friendly

Jazz Pharmaceuticals Inc.

JAZZ PHARMACEUTICALS INC. (Palo Alto CA) has put the development of three drugs in its pipeline on hold, in a bid to save cash as it seeks to resolve interest payment issues with its bond holders, a company spokesman said. "The interest issue has been the biggest overhang for our company and we continue to be in discussions with our senior secured note-holders to try to resolve that," Executive Director of Corporate Development Willie Quinn said. The company, which has yet to make profit, had failed to make its fourth-quarter interest payment on its $119.5 million senior secured notes. "If we resolve the default situation, then being profitable is a great thing, but until we have settled our differences with the note-holders, profitability is a secondary consideration," Quinn said. The company, which currently markets sleep disorder drug Xyrem and social anxiety disorder treatment Luvox CR, plans to continue the development of its experimental drug to treat fibromyalgia, a chronic pain syndrome. The fibromyalgia drug is currently being studied in a second late-stage trial.

"We have three other assets in various stages of development, but until we are fully reinstated with our note-holders, and probably until we get profitable, the development for those programs is currently on hold," Quinn said. The three halted candidates were in development as treatments for epilepsy and bipolar disorder; to treat restless legs syndrome; and as a treatment for epilepsy in patients who continue to have seizures while on stable anti-epileptic regimens. Jazz shares closed the week up 39 cents, or 11%, at $3.88.
COPYRIGHT 2009 MedContent Media, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CORPORATE; drug development
Article Type:Brief article
Date:Jun 29, 2009
Previous Article:Osiris Therapeutics Inc.
Next Article:Merck & Co. (Whitehouse Station NJ) sold $4.25 billion debt in four parts last week, according to a market source familiar with the sale.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |